Targeting SARS-CoV-2 Polymerase with New Nucleoside Analogues

Area of Science:

• Medicinal Chemistry
• Virology
• Drug Discovery

Background:

• While COVID-19 vaccines are available, effective FDA-approved antiviral treatments for SARS-CoV-2 remain limited.
• Existing antiviral strategies often involve repurposing drugs, with some nucleoside analogues showing promise against the virus's RNA-dependent RNA polymerase.

Purpose of the Study:

• To synthesize novel nucleoside analogues with modifications to the sugar moiety, replacing it with a quinazoline entity.
• To explore the potential of these new compounds as inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase.

Main Methods:

• Synthesis of novel quinazoline-based nucleoside analogues using various nucleobase derivatives.
• In vitro evaluation of the synthesized compounds for their inhibitory activity against the SARS-CoV-2 polymerase.

Main Results:

• Five new nucleoside analogues were successfully synthesized and characterized.
• Initial in vitro assays demonstrated inhibitory activity of these novel compounds against the target SARS-CoV-2 polymerase.

Conclusions:

• The synthesized quinazoline-based nucleoside analogues represent a promising new class of potential antiviral agents against SARS-CoV-2.
• Further research and development could lead to effective therapeutic options for COVID-19 treatment.